Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanotherapeutics and the Vaccine Branch of the National Cancer Institute Enter Into Cooperative Research and Development Agreement (CRADA)

Abstract:
Nanotherapeutics, Inc. announced today that it has entered into a two year Cooperative Research and Development Agreement (CRADA) with the Vaccine Branch of the National Cancer Institute (NCI) to produce HIV peptide oral vaccine nanoparticles using the company's proprietary technology. The collaboration with NCI will employ the company's nanoparticle delivery system, which enables oral targeted delivery of macromolecules such as peptides, to facilitate oral delivery in the GI tract to improve immune response.

Nanotherapeutics and the Vaccine Branch of the National Cancer Institute Enter Into Cooperative Research and Development Agreement (CRADA)

ALACHUA, FL | Posted on August 7th, 2007

James D. Talton, Ph.D., President of Nanotherapeutics and co-founder of the company, is the company's principal investigator on the project. Dr. Talton said, "The CRADA marks a significant milestone for the company and an important step in the development of novel HIV vaccines. When the NCI came to us to request our help in their HIV oral vaccine project, naturally, we were excited that our technology was recognized by them and that the Vaccine Branch had chosen to collaborate with us in this vital area of HIV research and development."

Also commenting on the CRADA, Mento A. "Chuck" Soponis, Chairman and CEO of Nanotherapeutics said, "This recognition is further validation of the work Dr. Talton and our scientists have been conducting over the past several years in the area of stabilized particle-based vaccine delivery. Entering into this collaborative relationship with the NCI's Vaccine Branch, demonstrates both the scientific and competitive strength of Nanotherapeutics."

In 2005, Nanotherapeutics received funding from National Institute on Drug Abuse (NIDA) to develop an oral nanoparticle medication to treat opiate addiction. The company also received funding from the National Institute of Allergy and Infectious Diseases (NIAID), as part of the National Institutes of Health (NIH) research program on Medical Countermeasures against Radiological and Nuclear Threats, to improve the delivery of an injectable treatment, and from Project Bioshield.

####

About Nanotherapeutics, Inc.
Nanotherapeutics Inc., an emerging specialty pharmaceutical company with expertise in the early-stage development of pharmaceuticals, is a privately held corporation located in Florida. The company is a provider of specialized drug delivery systems that use the company’s discoveries in nanotechnology to develop novel drug therapies or improved formulations for existing therapies. The company employs several platform technologies to manipulate and enhance the properties of drugs. These technologies can be employed with new chemical entities or with generic drugs and can be used with the spectrum of existing drug types ranging from small synthetic molecules to large recombinant macromolecules.

Significant advances have been made in the area of nanometer-scale particle delivery and Nanotherapeutics has created three proprietary drug delivery technologies: NanoQUAD™, NanoDRY™, and NanoCOAT™. These specialized proprietary techniques can improve the release rate and enhance both the rate and extent of drug uptake, thus increasing bioavailability. The consequences of these changes include more consistent drug therapy with potentially reduced dose and dose frequency requirements and fewer side effects.

For more information, please click here

Contacts:
Nanotherapeutics
Chuck Soponis
386-462-9663
Chairman & CEO

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014

Journal Nanotechnology Progress International (JONPI), 2014, Volume 5, Issue 1, pp 1-24 October 22nd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Announcements

NanoTechnology for Defense (NT4D) October 22nd, 2014

Mechanism behind nature's sparkles revealed October 22nd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Research partnerships

Brookhaven Lab Launches Computational Science Initiative:Leveraging computational science expertise and investments across the Laboratory to tackle "big data" challenges October 22nd, 2014

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Nitrogen Doped Graphene Characterized by Iranian, Russian, German Scientists October 21st, 2014

Crystallizing the DNA nanotechnology dream: Scientists have designed the first large DNA crystals with precisely prescribed depths and complex 3D features, which could create revolutionary nanodevices October 20th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE